MSX2 and breast cancer: In agreement with our previous findings, cytoplasmic Msx2 was associated with longer breast cancer-specific survival (BCSS) (P = 0.049), recurrence-free survival (RFS) (P = 0.029), and overall survival (OS) (P = 0.019) (Figure 3).